BCLC stage B2またはB3の肝細胞癌に対するレンバチニブの多施設共同前向き観察研究の中間報告

DOI Web Site Web Site 参考文献5件

書誌事項

タイトル別名
  • Lenvatinib for patients with BCLC stage B2/B3 hepatocellular carcinoma: interim analysis of a multicentre prospective observational study
  • BCLC stage B2 マタワ B3 ノ カン サイボウ ガン ニ タイスル レンバチニブ ノ タシセツ キョウドウ マエムキ カンサツ ケンキュウ ノ チュウカン ホウコク

この論文をさがす

抄録

<p>Lenvatinib (LEN) is a standard of care for patients with advanced hepatocellular carcinoma that has a high objective response rate (ORR). However, LEN is indicated only for patients with reserved liver function. We, therefore, posited that using LEN in **** (BCLC) stage B2 or B3 may be beneficial and conducted a prospective observational study in this context. In this paper, we report the results of that study in 15 initial patients. Three patients terminated LEN at 4.9 months of the median observation period, two because of disease progression and one because of an adverse event. The objective response rate (ORR) was 13% and 67% in response evaluation criteria in solid tumors (RESCIT) v1.1 and modified response evaluation criteria in solid tumors (mRECIST), respectively. We wish to continue the study to confirm survival benefits.</p>

収録刊行物

  • 肝臓

    肝臓 61 (5), 273-275, 2020-05-01

    一般社団法人　日本肝臓学会

参考文献 (5)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ